ClinicalTrials.gg
Active, not recruitingNCT06637371Updated Oct 30, 2026

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

A Phase 1 interventional study of AMG 691 and Placebo in Asthma, sponsored by Amgen. Active, not recruiting at 21 sites in 5 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Asthma by Amgen — none open to participants now, 2 under way, none of them phase 3. Asthma · Amgen.

Enrollment
10th of 13
21 · median 31
Started
2024
with 1 other
Phase 1
7 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Asthma by Amgen, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 1, and was the 12th registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 13 studies in Asthma by Amgen is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Asthma by Amgen as a file.
02

Study summary

The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • AMG 691
  • Pulmonology
  • Immunology
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Part A and B

  • Participants must be capable of giving and have provided informed consent.
  • Participants must be 18 to 65, inclusive at time of signing of informed consent.
  • Participants must have a between 18.0 to 30 kg/m\^2 and total body weight ≥ 40 kg at screening.
  • Participants must be overtly healthy as determined by the investigator based on medical evaluation and study screening procedures.
  • Female participants must be of non-.

Inclusion Part C

  • Participants must be capable of giving informed consent and have provided informed consent.
  • Participants must be 18 to 70, inclusive at time of signing of informed consent.
  • Body mass index between 18.0 to 35 kg/m\^2 and total body weight ≥ 40 kg at screening.
  • Participants must have documentation of physician diagnosed asthma for ≥ 12 months prior to screening.
  • Participants must have documented bronchodilator responsiveness of (FEV1) ≥ 10% in the 10 years before screening or at the screening visit.
  • Participants must have a pre-bronchodilator percent predicted FEV1 ≥ 50% at screening visit and Day -1. For participants on high-dose ICS, participants must have a percent-predicted FEV1 ≥ 70% at screening visit and on day -1.
  • Participants must have peripheral blood eosinophils ≥ 200 cells/μl at screening visit and Day -1.
  • Participants must have a fractional exhaled nitric oxide (FeNO) ≥ 25 ppb at screening visit and Day -1.
  • Participant must not use inhaled (ICS) or must be treated with low-dose, medium-dose, or high-dose ICS and on a stable dose for a minimum of 12 weeks prior to screening.

Exclusion (applicable to all study parts)

  • History of (except for in situ cervical cancer or surgically excised non-melanoma skin cancer occurring more than 5 years prior to randomization).
  • History of anaphylaxis or to biologic therapy or sensitivity to mammalian derived products.
  • History of immunodeficiency or history of severe infection within the last 3 years requiring IV antibiotics.
  • History of tuberculosis (TB), TB symptoms, or positive interferon gamma release assay.
  • History of untreated or unresolved helminthic infection within 24 weeks of day 1.
  • Positive (HIV) antibodies, core antigen, hepatitis B core antibody, or virus (HCV) ribonucleic acid (RNA).
  • Male participants unwilling to follow requirements.

Additional Exclusion for Part C only

  • Female of childbearing potential not willing to use 2 methods of contraception with one being a highly effective method of contraception.
  • History of pulmonary disease that may interfere with interpretation of study results.
  • History of upper respiratory infection within 6 weeks of screening.
  • Asthma Control Questionnaire (ACQ-6) > 3.
  • Asthma symptoms or exacerbations requiring 2 or more systemic corticosteroid bursts (≥10 mg/day prednisone or equivalent for ≥ 3 days each) in the previous 12 months.
  • More than one hospitalization or emergency department visit in the last year.
  • History of life-threatening asthma exacerbation after the 12 years age requiring admission to intensive care unit.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Part A: Single Ascending Dose (SAD)

    Healthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.

    Drug: AMG 691 · Drug: Placebo

  • Experimental
    Part B: Multiple Ascending Dose (MAD)

    Healthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.

    Drug: AMG 691 · Drug: Placebo

  • Experimental
    Part C: Multiple Dose

    Participants with mild-to-moderate asthma will be randomized in a 2:1 ratio to receive either AMG 691 or placebo.

    Drug: AMG 691 · Drug: Placebo

Interventions

  • DrugAMG 691

    Subcutaneous (SC) injection

  • DrugPlacebo

    SC injection

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. Serious AEs (SAEs) are defined as any untoward medical occurrence that, meet at least 1 of the following serious criteria: Immediately life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect. Includes AEs of interest (AEOI), and AEs leading to discontinuation.

    Time frame: Up to approximately 11 months

Secondary outcomes

  1. Maximum Concentration (Cmax) of AMG 691

    Time frame: Up to approximately 11 months

  2. Area Under the Curve (AUC) of AMG 691

    Time frame: Up to approximately 11 months

07

Study locations

21 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 29 months after the start.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 29 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Oct 16, 2024
Primary completionEst.
Apr 10, 2027
CompletionEst.
Apr 10, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06637371
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 16, 2024
Primary completion
Apr 10, 2027 (estimated)
Completion
Apr 10, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion